Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?
Publication
, Journal Article
Navar, AM; Mulder, HM; Wojdyla, DM; Peterson, ED
Published in: Circulation. Cardiovascular quality and outcomes
January 2020
Duke Scholars
Published In
Circulation. Cardiovascular quality and outcomes
DOI
EISSN
1941-7705
ISSN
1941-7713
Publication Date
January 2020
Volume
13
Issue
1
Start / End Page
e006019
Related Subject Headings
- United States
- Treatment Outcome
- Serine Proteinase Inhibitors
- Risk Factors
- Randomized Controlled Trials as Topic
- Practice Patterns, Physicians'
- PCSK9 Inhibitors
- Lipids
- Humans
- Dyslipidemias
Citation
APA
Chicago
ICMJE
MLA
NLM
Navar, A. M., Mulder, H. M., Wojdyla, D. M., & Peterson, E. D. (2020). Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors? Circulation. Cardiovascular Quality and Outcomes, 13(1), e006019. https://doi.org/10.1161/circoutcomes.119.006019
Navar, Ann Marie, Hillary M. Mulder, Daniel M. Wojdyla, and Eric D. Peterson. “Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?” Circulation. Cardiovascular Quality and Outcomes 13, no. 1 (January 2020): e006019. https://doi.org/10.1161/circoutcomes.119.006019.
Navar AM, Mulder HM, Wojdyla DM, Peterson ED. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors? Circulation Cardiovascular quality and outcomes. 2020 Jan;13(1):e006019.
Navar, Ann Marie, et al. “Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?” Circulation. Cardiovascular Quality and Outcomes, vol. 13, no. 1, Jan. 2020, p. e006019. Epmc, doi:10.1161/circoutcomes.119.006019.
Navar AM, Mulder HM, Wojdyla DM, Peterson ED. Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors? Circulation Cardiovascular quality and outcomes. 2020 Jan;13(1):e006019.
Published In
Circulation. Cardiovascular quality and outcomes
DOI
EISSN
1941-7705
ISSN
1941-7713
Publication Date
January 2020
Volume
13
Issue
1
Start / End Page
e006019
Related Subject Headings
- United States
- Treatment Outcome
- Serine Proteinase Inhibitors
- Risk Factors
- Randomized Controlled Trials as Topic
- Practice Patterns, Physicians'
- PCSK9 Inhibitors
- Lipids
- Humans
- Dyslipidemias